www.fdanews.com/articles/159664-puma-starts-phase-ii-clinical-trial-of-tumor-drug

Puma Starts Phase II Clinical Trial of Tumor Drug

October 8, 2013

Puma Biotechnology has started a Phase II trial of neratinib, a cancer drug targeting patients with solid tumors with HER-2 mutations.
Pharmaceutical Business Review